Project 4: Synucleinopathy Biomarkers and the Skin

$266,893U54FY2015NSNIH

Vanderbilt University, Nashville TN

Investigators

Linked publications & trials

Paper 38468536 Paper 38366572 Paper 36657992 Paper 36601916 Paper 36442207 Paper 36151960 Paper 35802513 Paper 35230654 Paper 34897579 Paper 34739766 Paper 34729682 Paper 34669076 Paper 34510135 Paper 34416163 Paper 34244806 Paper 33991233 Paper 33947784 Paper 33755181 Paper 33739123 Paper 33712946 Paper 33705537 Paper 33554315 Paper 33043073 Paper 33025279 Paper 32979782 Paper 32906173 Paper 32906171 Paper 32833276 Paper 32673517 Paper 32546656 Paper 32516630 Paper 32450546 Paper 32320519 Paper 32246226 Paper 32223377 Paper 32206478 Paper 32056310 Paper 32025029 Paper 31996627 Paper 31996623 Paper 31733702 Paper 31706219 Paper 31673840 Paper 31621598 Paper 31517701 Paper 31515103 Paper 31456212 Paper 31327626 Paper 31152011 Paper 31122601 Paper 31077434 Paper 31054608 Paper 31021876 Paper 30890343 Paper 30882602 Paper 30861073 Paper 30783821 Paper 30637592 Paper 30571543 Paper 30539785 Paper 30341962 Paper 30334929 Paper 30328032 Paper 30170741 Paper 30151691 Paper 30105358 Paper 30053970 Paper 30037689 Paper 30019293 Paper 29728530 Paper 29680425 Paper 29549458 Paper 29508455 Paper 29436737 Paper 29405350 Paper 29352098 Paper 29343526 Paper 29313153 Paper 29293269 Paper 29289840 Paper 29287113 Paper 29254663 Paper 29237794 Paper 29234869 Paper 29196937 Paper 29111419 Paper 29076058 Paper 29025750 Paper 28821991 Paper 28808164 Paper 28713844 Paper 28674865 Paper 28620715 Paper 28596752 Paper 28582870 Paper 28521050 Paper 28490649 Paper 28472861 Paper 28401297 Paper 28395083

Abstract

ABSTRACT In this proposal, we wish to determine the utility of cutaneous alpha-synuclein (?SN) measured in skin biopsies as a biomarker in the alpha-synucleinopathies with autonomic failure [multiple system atrophy (MSA) and the Lewy body disorders, pure autonomic failure (PAF) and Parkinson's disease (PD)]. This will be accomplished in 3 studies. In the first study, we will determine the cutaneous deposition of ?SN in multiple system atrophy and contrast it with the Lewy body alpha-synucleinopathies with orthostatic hypotension (PD and PAF) in a cross-sectional study and subsequent longitudinal study. We anticipate that individuals with MSA will have lower ?SN deposition in cutaneous skin biopsies than similarly affected individuals with the Lewy body alpha- synucleinopathies (PD and PAF) and orthostatic hypotension assessed in a cross-sectional study, and that low cutaneous ?SN deposition will predict worse prognosis in a longitudinal study. In the second study, we will determine the amount of ?SN in cutaneous autonomic fibers from post-mortem scalp and abdomen skin of pathologically confirmed patients with MSA, PD and healthy and diseased controls. We anticipate that measures of ?SN immunoreactivity in the skin will be greater in patients with PD than patients with MSA, and that ?SN immunoreactivity in PD, but not MSA, will correlate with neuropathological scores and the United Parkinson's Disease Rating Scale scores. In the third study we will determine whether ?SN deposition in the skin is correlated with myocardial noradrenergic innervation as indicated by cardiac sympathetic neuroimaging in the alpha-synucleinopathies with orthostatic hypotension. We anticipate that individuals with MSA will have low ?SN deposition in cutaneous skin biopsies and normal cardiac 6-[18F]fluorodopamine-derived radioactivity, whereas individuals with PD or PAF will have high ?SN deposition and low cardiac 6- [18F]fluorodopamine-derived radioactivity. If successful, the proposed studies will provide a valid diagnostic and prognostic biomarker and be a first step in the development of a surrogate endpoint for disease modifying and neuroprotective therapies in the alpha-synucleinopathy neurodegenerative diseases.

View original record on NIH RePORTER →